Neelim Healthcare Consulting
Neelim

Dermatology Prometric exam questions

Exam-length papers covering every published domain for Dermatology.

Tell us which regulator you are sitting and we send the bank prepared for that authority's exam.

For DHA · DOH · MOHAP · SHA · SCFHS · QCHP · NHRA · OMSB · Kuwait MOHDHA DER5421OMSB OEDPass mark DHA 65% · SCFHS 65% · QCHP 65% · OMSB 65% · Kuwait MOH 65%From 3 papers · ~155 Qs each
AED 319one-time
About a third of one exam fee
Request this question bank

Tell us your authority and we send the bank for that exam, usually the same day.

Or sit 25 questions free first →

What is riding on this exam

~AED 1,030
DHA exam fee, per attempt
Paid again on every re-sit. Other regulators' fees are in the table below.
3
UAE attempts - in total
Shared across DHA, DOH, MOHAP and SHA, not three each. Saudi, Qatar, Oman and Kuwait rules are in the FAQ.
65%
Pass mark, by regulator
DHA 65%, SCFHS 65%, QCHP 65%, OMSB 65%, Kuwait MOH 65%. Other regulators in the table below.

One failed attempt costs you the fee again, plus months of delay on your licence, your visa and your start date. This bank costs about a third of one exam fee.

Every regulator: format, pass marks and fees for all GCC licensing exams, each from the regulator's own documents.

The Dermatology exam at a glance

DHA (UAE) publishes a Dermatology exam of 150 MCQs in 3 hours with a 65% pass mark; DOH (UAE) publishes a Dermatology exam of 100 MCQs in 2 hours, scored pass or fail; SCFHS (Saudi Arabia) publishes a Dermatology exam of 200 MCQs in 240 minutes with a 65% pass mark; QCHP (Qatar) publishes a Dermatology exam of 150 MCQs in 3 hours with a 65% pass mark; OMSB (Oman) publishes a Dermatology exam of 100 MCQs in 150 minutes with a 65% pass mark; Kuwait MOH (Kuwait) publishes a Dermatology exam of 150 MCQs in 170 minutes with a 65% pass mark. MOHAP, SHA, NHRA do not publish Dermatology-specific figures; their regulator-wide format and pass-mark rules are in the full table.

DHA · UAE
Specialist Dermatology (DER5421)
150 MCQs in 3 hours · pass mark 65% · USD 280 (about AED 1,030) · checked September 2026
DOH · UAE
Specialist Dermatology CBT
100 MCQs in 2 hours · pass mark Pass / fail only · AED 550 · checked October 2026
SCFHS · Saudi Arabia
Saudi Classification Examination - Dermatology
200 MCQs in 240 minutes · pass mark 65% · checked October 2026
QCHP · Qatar
Specialist Dermatology
150 MCQs in 3 hours · pass mark 65% · checked September 2026
OMSB · Oman
Omani Examination for Dermatology (OED)
100 MCQs in 150 minutes · pass mark 65% · USD 220 (about OMR 80) · checked September 2026
Kuwait MOH · Kuwait
Dermatology - Registrar
150 MCQs in 170 minutes · pass mark 65% · checked September 2026

From each regulator's own exam documents; the DHA row is from the DHA CBT Guideline, Sep 2026. Every other regulator is in the full GCC table.

Try two questions from this bank

Original questions from the bank - pick an answer to see the rationale and reference.

Q1Papulosquamous and Eczematous Dermatoses

A 45-year-old woman with plaque psoriasis has been on a biologic for 6 months. Her PASI has fallen from 18 to 1.5 and her Dermatology Life Quality Index (DLQI) is 1. How should these results be interpreted?

Choose an answer to see the rationale.

Q2Hair, Nail, Adnexal and Mucous Membrane Disorders

A 34-year-old woman with moderate-to-severe hidradenitis suppurativa has failed topical clindamycin and a 12-week course of oral clindamycin with rifampicin. Which biologic class has established randomised evidence and regulatory approval for this indication?

Choose an answer to see the rationale.

Not sure where you stand? Sit 25 of these questions free, timed at real exam pace, and see which domains you are weakest in.

Take the free mock exam →

Liked those? The full bank has 469 questions at this standard - every one with a rationale and a reference.

Get the full bank - AED 319

What's inside

  • ✓3 to 6 full-length papers (~155 Q each)
  • ✓No question repeated between papers
  • ✓Four options, one unambiguous best answer
  • ✓A full rationale on every question
  • ✓A real guideline or textbook reference
  • ✓Every sub-topic in the published blueprint
  • ✓Researched by Neelim's exam research team
  • ✓Prepared for your authority's exam, not a generic set

The Dermatology exam in every GCC country

Dermatology licensing exam in every GCC country
RegulatorExamFormatPass markFee per attempt
Specialist Dermatology (DER5421)
150 MCQs in 3 hours65%USD 280 (about AED 1,030)
DOH
Abu Dhabi, Al Ain and Al Dhafra
Practise →
Specialist Dermatology CBT
100 MCQs in 2 hoursPass / fail onlyAED 550
SCFHS
Kingdom of Saudi Arabia
Practise →
Saudi Classification Examination - Dermatology
200 MCQs in 240 minutes65%Not published
QCHP
State of Qatar
Practise →
Specialist Dermatology
150 MCQs in 3 hours65%Not published
OMSB
Sultanate of Oman
Practise →
Omani Examination for Dermatology (OED)
100 MCQs in 150 minutes65%USD 220 (about OMR 80)
Kuwait MOH
State of Kuwait
Practise →
Dermatology - Registrar
150 MCQs in 170 minutes65%Not published
MOHAP
Northern Emirates - Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah
Practise →
MOHAP licensing exam
Regulator-wide format
Computer-basedNot publishedNot published
SHA
Emirate of Sharjah
Practise →
SHA licensing exam
Regulator-wide format
Set at assessmentNot publishedNot published
NHRA
Kingdom of Bahrain
Practise →
NHRA licensing exam
Regulator-wide format
Prometric CBTNot publishedNot published

Highlighted rows publish figures for this exact Dermatology exam; the others show the regulator's general rules.

From each regulator's own exam pages; anything a regulator does not publish says so. Assessment mode also depends on your licence title, so confirm your route on your eligibility notice.

Try 15 free Dermatology questions with answersDifferent from the samples on this page - each with a full explanationStart →

What the Dermatology exam covers

The published blueprint for this exam breaks into 13 domains and 235 testable sub-topics. Our bank covers every one of them - here is the full map, so you can see exactly what you are expected to know.

Basic Science, Skin Biology, Cutaneous Immunology and Dermatopathology~8% (est.; DHA lists 'Basic Science'; SCFHS Part One allots 10% anatomy/structure/development, 10% innate immunity, 10% adaptive immunity, 5% keratinocytes and dermal-epidermal cohesion)17 topics
  • Embryology and development of skin, appendages and neural crest melanocyte migration
  • Epidermal structure: keratinocyte differentiation, cornified envelope, filaggrin and the skin barrier
  • Desmosomes, hemidesmosomes and the dermal-epidermal junction: target antigens of blistering disease
  • Dermal connective tissue: collagen types, elastic fibres, ground substance and wound healing phases
  • Subcutaneous fat, cutaneous vasculature, lymphatics and cutaneous nerves
  • Melanocyte biology, melanogenesis, Fitzpatrick skin phototypes and photobiology (UVA/UVB, MED, action spectra)
  • +11 more in the bank
Papulosquamous and Eczematous Dermatoses~10% (est.; DHA heading; SCFHS Final Written allots 10% to T-cell mediated inflammatory disease)18 topics
  • Psoriasis vulgaris: clinical variants (plaque, guttate, inverse, erythrodermic, pustular), Auspitz sign, Koebner phenomenon
  • Psoriasis severity assessment (PASI, BSA, DLQI) and treat-to-target thresholds
  • Topical, phototherapy, conventional systemic (methotrexate, ciclosporin, acitretin) and biologic (anti-TNF, IL-12/23, IL-17, IL-23) sequencing in psoriasis
  • Generalised pustular psoriasis and von Zumbusch flare - an inpatient emergency
  • Psoriatic arthritis: patterns, CASPAR criteria, dactylitis, enthesitis, nail involvement, screening tools
  • Psoriasis comorbidities: metabolic syndrome, cardiovascular risk, IBD, uveitis, depression
  • +12 more in the bank
Urticaria, Erythemas, Drug Eruptions, Purpura and Cutaneous Vasculitis~9% (est.; DHA heading 'Urticaria, Erythemas, Purpura and Connective Tissue Diseases'; SCFHS Final Written allots 10% to neutrophil/eosinophil and humoral-mediated disease)19 topics
  • Acute vs chronic spontaneous urticaria: definition, natural history, autoimmune (autologous serum) urticaria
  • Inducible/physical urticarias: dermographism, cholinergic, cold, delayed pressure, solar, aquagenic
  • Stepwise urticaria therapy: second-generation antihistamine up-dosing, omalizumab, ciclosporin; role and limits of steroids
  • Angioedema: histaminergic, ACE-inhibitor induced and hereditary/acquired C1-inhibitor deficiency - C4 and C1-INH testing and icatibant/C1-INH concentrate
  • Anaphylaxis recognition and adrenaline administration in the dermatology clinic
  • Urticarial vasculitis and hypocomplementaemic urticarial vasculitis syndrome
  • +13 more in the bank
Vesiculobullous and Autoimmune Blistering Diseases~5% (est.; DHA heading; SCFHS Final Written allots 5%)16 topics
  • Pemphigus vulgaris and pemphigus foliaceus: desmoglein compensation theory, Nikolsky sign, mucosal-dominant vs mucocutaneous
  • Paraneoplastic pemphigus and its associated malignancies and bronchiolitis obliterans
  • IgA pemphigus, pemphigus vegetans and drug-induced pemphigus (penicillamine, captopril)
  • Bullous pemphigoid: BP180/BP230, urticarial prodrome, gliptin- and checkpoint-inhibitor-associated cases
  • Mucous membrane (cicatricial) pemphigoid and ocular scarring - urgent ophthalmology referral
  • Pemphigoid gestationis and its neonatal implications
  • +10 more in the bank
Connective Tissue Disease, Dermal, Subcutaneous, Metabolic and Systemic Skin Disease~8% (est.; DHA headings 'Metabolic, Systemic Diseases and Disorders of Dermal Connective Tissues and Subcutaneous Fat' and 'Skin Manifestations of Other Diseases'; SCFHS Final Written allots 10% plus 5% metabolic/systemic)19 topics
  • Cutaneous lupus erythematosus: acute, subacute (anti-Ro), discoid, tumid, lupus panniculitis and chilblain lupus
  • Systemic lupus: ACR/EULAR criteria, antibody profiles, photoprotection, hydroxychloroquine dosing and retinal monitoring
  • Dermatomyositis: heliotrope rash, Gottron papules, shawl and holster sign, myositis-specific antibodies (anti-MDA5, anti-TIF1-gamma) and malignancy screening
  • Systemic sclerosis and limited cutaneous disease/CREST; skin scoring, digital ulcers, Raynaud management, scleroderma renal crisis
  • Localised scleroderma/morphea, eosinophilic fasciitis and nephrogenic systemic fibrosis
  • Mixed connective tissue disease, Sjogren syndrome and antisynthetase syndrome skin signs
  • +13 more in the bank
Cutaneous Infections, Infestations, Bites and Sexually Transmitted Infections~10% (est.; DHA heading 'Infections, Infestations and Bites'; SCFHS Final Written allots 10%)19 topics
  • Superficial bacterial infection: impetigo, ecthyma, folliculitis, furuncle/carbuncle and decolonisation of recurrent S. aureus
  • Cellulitis and erysipelas: severity classification, mimics (pseudocellulitis), antibiotic choice and MRSA considerations
  • Necrotising fasciitis and Fournier gangrene: LRINEC, red flags and immediate surgical referral
  • Staphylococcal scalded skin syndrome and toxic shock syndrome
  • Cutaneous tuberculosis (lupus vulgaris, scrofuloderma), atypical mycobacteria (M. marinum, M. abscessus) and leprosy classification, reactions and MDT
  • Superficial fungal infection: tinea capitis/corporis/cruris/pedis/unguium, terbinafine-resistant Trichophyton indotineae, KOH and culture
  • +13 more in the bank
Cutaneous Neoplasms and Skin Cancer~9% (est.; DHA heading 'Cutaneous Neoplasms'; SCFHS allots 10% in both Part One and Final Written)18 topics
  • Benign epidermal and appendageal tumours: seborrhoeic keratosis, epidermal naevus, syringoma, trichoepithelioma, pilomatricoma, hidradenoma
  • Cysts and benign mesenchymal tumours: epidermoid/pilar cyst, dermatofibroma, lipoma, neurofibroma, keloid and hypertrophic scar
  • Vascular tumours and malformations: infantile haemangioma (and propranolol), pyogenic granuloma, cherry angioma, port-wine stain, Kaposi sarcoma
  • Actinic keratosis, actinic cheilitis, field cancerisation and topical field therapy (5-FU, imiquimod, PDT)
  • Bowen disease, erythroplasia of Queyrat and keratoacanthoma
  • Basal cell carcinoma: subtypes, high-risk features, Mohs indications, hedgehog inhibitors for locally advanced/metastatic disease
  • +12 more in the bank
Hair, Nail, Adnexal and Mucous Membrane Disorders~7% (est.; DHA heading 'Adnexal, Hair, Nails and Mucous Membranes Diseases'; SCFHS allots 5% hair/nail/mucosa plus 5% skin appendages)18 topics
  • Hair cycle physiology and the trichogram/hair pull, trichoscopy and scalp biopsy
  • Androgenetic alopecia in men and women: Hamilton-Norwood/Ludwig scales, minoxidil, finasteride/dutasteride, antiandrogens, PRP evidence
  • Telogen effluvium, anagen effluvium and drug-induced hair loss
  • Alopecia areata: patterns, nail signs, prognosis, intralesional and topical therapy, JAK inhibitors
  • Cicatricial alopecias: lichen planopilaris, frontal fibrosing alopecia, discoid lupus, central centrifugal cicatricial alopecia, folliculitis decalvans, dissecting cellulitis
  • Tinea capitis, kerion, trichotillomania and traction alopecia
  • +12 more in the bank
Pigmentary Disorders and Photodermatoses~6% (est.; DHA heading; SCFHS Final Written groups pigmentary/adnexal/physical-agent disorders at 10%, Part One allots 5% pigmentation)18 topics
  • Vitiligo: segmental vs non-segmental, VASI/VIDA activity assessment, associated autoimmunity screening
  • Vitiligo therapy: topical steroids/calcineurin inhibitors, ruxolitinib cream, NB-UVB, excimer, surgical grafting, depigmentation for extensive disease
  • Melasma: epidermal/dermal patterns, Wood lamp, hormonal and UV/visible-light triggers, tinted broad-spectrum photoprotection
  • Melasma treatment: hydroquinone and non-hydroquinone lighteners, triple combination, tranexamic acid, chemical peels, laser cautions
  • Post-inflammatory hyperpigmentation and hypopigmentation, especially in skin of colour
  • Ochronosis, drug-induced pigmentation (minocycline, amiodarone, antimalarials, chemotherapy) and heavy-metal deposition
  • +12 more in the bank
Pediatric Dermatology and Genodermatoses~8% (est.; DHA heading 'Pediatric Dermatology'; SCFHS Final Written allots 10% to genodermatosis and paediatric dermatology, Part One 10% genodermatosis)18 topics
  • Neonatal transient conditions: erythema toxicum neonatorum, transient neonatal pustular melanosis, milia, miliaria, neonatal cephalic pustulosis
  • Napkin/diaper dermatitis and its differential (candidiasis, seborrhoeic, psoriasis, Langerhans cell histiocytosis, zinc deficiency)
  • Infantile haemangioma: PHACE and LUMBAR associations, indications and safety of propranolol
  • Vascular malformations: port-wine stain, Sturge-Weber, Klippel-Trenaunay, lymphatic and venous malformations
  • Congenital melanocytic naevi: size classification, neurocutaneous melanosis risk, surveillance vs excision
  • Paediatric atopic dermatitis: severity, growth and sleep impact, food-allergy testing pitfalls, topical steroid phobia counselling
  • +12 more in the bank
Dermatologic Therapeutics and Pharmacology~7% (est.; SCFHS Part One allots 10% to therapeutics; DHA references Wolverton Comprehensive Dermatologic Drug Therapy)18 topics
  • Topical corticosteroid potency classes, vehicle selection, fingertip units, quantity prescribing and local/systemic adverse effects
  • Topical calcineurin inhibitors, PDE4 inhibitors, topical JAK inhibitors, vitamin D analogues and topical retinoids
  • Keratolytics, tar, dithranol, antiseptics and emollient/barrier-repair science
  • Systemic corticosteroids: tapering, bone protection, glycaemic effect, infection risk and steroid-sparing strategy
  • Methotrexate: dosing, folate, hepatotoxicity and pulmonary toxicity, drug interactions, contraception
  • Ciclosporin: nephrotoxicity, hypertension, duration limits and interaction profile
  • +12 more in the bank
Procedural, Surgical, Laser and Cosmetic Dermatology~8% (est.; DHA heading 'Procedural Dermatology'; SCFHS Final Written allots 10%)19 topics
  • Surgical anatomy and danger zones: facial nerve branches, temporal branch, spinal accessory nerve, superficial vessels
  • Local anaesthesia: lidocaine and bupivacaine dosing limits, adrenaline use in digits, nerve blocks, tumescent anaesthesia, toxicity management
  • Antisepsis, sterile technique, surgical site infection prevention and antibiotic prophylaxis indications
  • Anticoagulants and antiplatelets around skin surgery; bleeding and haematoma management
  • Biopsy and excision technique: shave, punch, curettage and electrodesiccation, elliptical excision, margin selection
  • Closure options: primary, second intention, flaps (advancement, rotation, transposition, interpolation) and full/split-thickness grafts
  • +13 more in the bank
Dermatologic Emergencies, Patient Safety, Professionalism and Ethics~5% (est.; DHA lists 'Patient Safety' and 'Professionalism and Ethics' as separate coverage headings for both bands; SCFHS states these are embedded across domains)18 topics
  • Recognition and immediate management of dermatologic emergencies: SJS/TEN, DRESS, AGEP, erythroderma, pustular psoriasis flare, purpura fulminans, necrotising fasciitis, eczema herpeticum, angioedema/anaphylaxis
  • Fluid, electrolyte, thermoregulation, analgesia and nutrition in the acutely denuded patient; when to transfer to burns/ICU
  • Multidisciplinary escalation and referral thresholds; safe handover (SBAR/ISBAR)
  • Patient safety principles: incident and near-miss reporting, root-cause analysis, never events, just culture
  • Medication safety: high-alert dermatology drugs, look-alike/sound-alike errors, teratogen controls and reconciliation
  • Specimen and laboratory safety: correct site marking, biopsy labelling, avoiding wrong-site surgery, WHO surgical safety checklist
  • +12 more in the bank

12 worked Dermatology practice questions

Original exam-style questions from the bank, spread across the blueprint domains. They are not real or recalled exam questions. Try each one, then open the answer for the rationale and reference. None of them appear in the free mock exam, so reading them will not spoil it.

  1. Question 1 · Papulosquamous and Eczematous Dermatoses

    A 29-year-old woman at 32 weeks gestation, with no personal history of psoriasis, develops fever, malaise and erythematous plaques in the groins and axillae fringed by tiny sterile pustules that extend centrifugally. Serum calcium is 1.95 mmol/L and albumin is low. What is the most likely diagnosis?

    1. APemphigoid gestationis
    2. BImpetigo herpetiformis (generalised pustular psoriasis of pregnancy)
    3. CAcute generalised exanthematous pustulosis
    4. DPolymorphic eruption of pregnancy
    Show answer and explanation

    Correct answer: B. Impetigo herpetiformis (generalised pustular psoriasis of pregnancy)

    Impetigo herpetiformis is generalised pustular psoriasis occurring in pregnancy, typically in the late second or third trimester, beginning in flexures with expanding rings of sterile pustules and accompanied by fever, hypocalcaemia and hypoalbuminaemia, with a risk of placental insufficiency requiring close fetal monitoring. Pemphigoid gestationis produces periumbilical urticarial plaques and tense bullae with linear C3 on direct immunofluorescence, AGEP follows a culprit drug within days, and polymorphic eruption of pregnancy is an itchy non-pustular eruption in abdominal striae without systemic upset.

    Reference: Ambros-Rudolph, Obstetric Dermatology, in Bolognia Dermatology, 5th ed., 2024; Namazi & Dadkhahfar, Dermatol Res Pract, 2018

  2. Question 2 · Urticaria, Erythemas, Drug Eruptions, Purpura and Cutaneous Vasculitis

    A patient of Han Chinese ancestry is to start carbamazepine for trigeminal neuralgia. Which pharmacogenetic test should be considered before prescribing, and why?

    1. AHLA-B*58:01, because it predicts allopurinol-induced severe cutaneous adverse reactions
    2. BTPMT genotype, because carbamazepine is metabolised by thiopurine methyltransferase
    3. CHLA-A*31:01, because it predicts carbamazepine-induced SJS/TEN in all ethnic groups equally
    4. DHLA-B*15:02, because it is strongly associated with carbamazepine-induced SJS/TEN in Southeast Asian populations
    Show answer and explanation

    Correct answer: D. HLA-B*15:02, because it is strongly associated with carbamazepine-induced SJS/TEN in Southeast Asian populations

    HLA-B*15:02 carriage confers a markedly increased risk of carbamazepine-induced SJS/TEN in Han Chinese, Thai, Malay and other Southeast Asian populations, and screening before initiation is recommended by regulators and CPIC. HLA-B*58:01 relates to allopurinol; HLA-A*31:01 is associated mainly with carbamazepine hypersensitivity syndrome/DRESS and maculopapular eruption in European and Japanese populations rather than being a universal SJS/TEN marker; TPMT is relevant to thiopurines, not carbamazepine.

    Reference: CPIC Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine (2017 update), Clin Pharmacol Ther

  3. Question 3 · Basic Science, Skin Biology, Cutaneous Immunology and Dermatopathology

    A 9-year-old child has blistering from birth at sites of friction, healing with atrophic scars and milia, dystrophic nail loss and progressive pseudosyndactyly of the hands. Genetic testing identifies biallelic COL7A1 mutations. Which ultrastructural component of the dermal-epidermal junction is defective?

    1. AKeratin 5/14 intermediate filaments within basal keratinocytes
    2. BAnchoring fibrils extending from the lamina densa into the papillary dermis
    3. CThe inner hemidesmosomal plaque containing plectin and BP230
    4. DAnchoring filaments crossing the lamina lucida
    Show answer and explanation

    Correct answer: B. Anchoring fibrils extending from the lamina densa into the papillary dermis

    COL7A1 encodes type VII collagen, the sole constituent of anchoring fibrils that loop from the lamina densa into the papillary dermis; their loss causes recessive dystrophic epidermolysis bullosa with sub-lamina densa cleavage, scarring, milia and mitten deformity. Keratin 5/14 defects cause epidermolysis bullosa simplex with intrabasal cleavage and minimal scarring. Plectin/BP230 plaque defects also cause simplex-type disease, and laminin-332 anchoring filament defects cause junctional EB with cleavage in the lamina lucida.

    Reference: Has C et al. Consensus reclassification of inherited epidermolysis bullosa. Br J Dermatol, 2020

  4. Question 4 · Pediatric Dermatology and Genodermatoses

    A newborn has a 2 cm well-circumscribed, hairless, membranous defect on the vertex of the scalp, present at birth and surrounded by a ring of long dark coarse hair. What is the most appropriate next step?

    1. AImmediate surgical excision and primary closure in the first week of life
    2. BImaging of the underlying skull and brain (ultrasound and/or MRI) to exclude cranial dysraphism or an underlying encephalocele before any manipulation
    3. CReassurance alone, as all lesions of this type heal without complication
    4. DEmpirical intravenous antibiotics for suspected congenital infection
    Show answer and explanation

    Correct answer: B. Imaging of the underlying skull and brain (ultrasound and/or MRI) to exclude cranial dysraphism or an underlying encephalocele before any manipulation

    The hair collar sign, a ring of coarse dark hair encircling a membranous scalp defect, is a marker of an underlying cranial neural tube closure defect such as a meningocele, encephalocele or heterotopic brain tissue, and imaging must precede any biopsy or excision to avoid catastrophic complications including CSF leak and meningitis. Simple non-membranous aplasia cutis congenita usually heals with an atrophic scar and can be managed conservatively, but this is the subgroup that requires investigation. Antibiotics are not indicated in the absence of infection.

    Reference: Drolet BA et al., 'Hair collar sign': marker for cranial dysraphism, Pediatrics (1995); Paller & Mancini, Hurwitz Clinical Pediatric Dermatology, 6th ed. (2022)

  5. Question 5 · Hair, Nail, Adnexal and Mucous Membrane Disorders

    A 45-year-old woman with a 2-year history of progressive vertex hair loss is scheduled for a scalp biopsy to distinguish a non-scarring from a scarring alopecia. Which biopsy approach gives the most information for this indication?

    1. AA single 2 mm punch biopsy from the centre of the bald vertex, sectioned vertically
    2. BA shave biopsy of the vertex including only epidermis and papillary dermis
    3. CAn elliptical biopsy of clinically normal occipital scalp
    4. DA 4 mm punch biopsy taken from active affected scalp, oriented parallel to the hair shafts, with horizontal (transverse) sectioning
    Show answer and explanation

    Correct answer: D. A 4 mm punch biopsy taken from active affected scalp, oriented parallel to the hair shafts, with horizontal (transverse) sectioning

    A 4 mm punch angled parallel to the hair shafts and carried into subcutaneous fat captures whole follicular units, and horizontal sectioning allows counting of terminal and vellus follicles, the terminal:vellus ratio and follicular density, which is the key discriminator in alopecia. A 2 mm punch samples too few follicles, and end-stage bald skin shows only fibrous tracts without diagnostic information. A shave biopsy misses the bulbs in the subcutis, and biopsying uninvolved scalp will not show the pathology.

    Reference: British Association of Dermatologists guidelines for the management of alopecia areata (2022) and Sperling's Atlas of Hair Pathology with Clinical Correlation, 3rd ed. (2021)

  6. Question 6 · Pigmentary Disorders and Photodermatoses

    Which statement most accurately distinguishes a photoallergic from a phototoxic drug reaction?

    1. APhototoxic reactions require previous sensitisation and can spread to covered skin, whereas photoallergic reactions occur on first exposure
    2. BPhototoxic reactions are typically eczematous and delayed by 24 to 48 hours, whereas photoallergic reactions look like exaggerated sunburn within hours
    3. CPhotoallergic reactions are cell-mediated, dose-independent, eczematous, delayed by 24 to 48 hours, may extend beyond sun-exposed skin, and are confirmed by photopatch testing
    4. DBoth types occur only with UVB and neither can be reproduced by testing
    Show answer and explanation

    Correct answer: C. Photoallergic reactions are cell-mediated, dose-independent, eczematous, delayed by 24 to 48 hours, may extend beyond sun-exposed skin, and are confirmed by photopatch testing

    Photoallergy is a type IV cell-mediated response to a photo-antigen: it requires prior sensitisation, is not dose-dependent, appears as delayed eczematous dermatitis 24 to 48 hours after exposure, may spread to covered skin, and is confirmed by photopatch testing. Phototoxicity is far commoner, needs no sensitisation, is dose-dependent, and produces an exaggerated sunburn with burning within minutes to hours confined to exposed skin, so the first two options invert the definitions. Most clinically important photosensitisers, including doxycycline, thiazides, amiodarone, voriconazole and non-steroidal anti-inflammatory drugs, act mainly through UVA, and reactions can be reproduced by phototesting or photopatch testing.

    Reference: Fitzpatrick's Dermatology in General Medicine, 9th edition, 2019; Rook's Textbook of Dermatology, 9th edition, 2016

  7. Question 7 · Dermatologic Emergencies, Patient Safety, Professionalism and Ethics

    The adult son of a 70-year-old woman with newly diagnosed metastatic melanoma asks the dermatologist not to tell his mother the diagnosis, saying it is culturally inappropriate and will destroy her hope. The patient has full capacity and has previously asked to be kept informed. What is the most appropriate course?

    1. AComply with the family's wish, as family-centred decision-making takes precedence in the region
    2. BExplore the son's concerns, then sensitively ask the patient herself how much she wishes to know and who she wants involved, and follow her stated preference
    3. CTell the son the family has no standing and disclose the diagnosis to the patient in his presence without further discussion
    4. DDisclose only to the son and document that the patient was deemed too fragile to be told
    Show answer and explanation

    Correct answer: B. Explore the son's concerns, then sensitively ask the patient herself how much she wishes to know and who she wants involved, and follow her stated preference

    The competent patient determines the flow of her own information, and the ethically robust solution is to acknowledge the family's protective motive while directly ascertaining the patient's own preference about disclosure and family involvement - a patient may validly delegate information to family, but that must be her choice. Simply complying with the son colludes in deception against her expressed wish to be informed. Dismissing the family confrontationally damages the therapeutic alliance without benefit. Disclosing only to the son and labelling her fragile is unjustified paternalism and a confidentiality breach.

    Reference: Beauchamp and Childress, Principles of Biomedical Ethics, 8th ed. (2019); General Medical Council, Decision Making and Consent (2020)

  8. Question 8 · Cutaneous Infections, Infestations, Bites and Sexually Transmitted Infections

    A 52-year-old man admitted in diabetic ketoacidosis develops unilateral facial pain, periorbital swelling, nasal discharge and a black necrotic eschar on the hard palate and nasal turbinates. Biopsy shows broad, ribbon-like, pauciseptate hyphae with wide-angle branching and angioinvasion. What is the most appropriate management?

    1. AUrgent surgical debridement plus intravenous liposomal amphotericin B, with aggressive correction of the ketoacidosis
    2. BOral voriconazole alone
    3. COral fluconazole with topical antiseptic packing
    4. DIntravenous ceftriaxone and metronidazole
    Show answer and explanation

    Correct answer: A. Urgent surgical debridement plus intravenous liposomal amphotericin B, with aggressive correction of the ketoacidosis

    Broad pauciseptate ribbon-like hyphae with angioinvasion in a ketoacidotic patient indicate rhino-orbito-cerebral mucormycosis, where survival depends on early surgical debridement, first-line liposomal amphotericin B and reversal of the underlying acidosis and hyperglycaemia. Voriconazole has no reliable activity against Mucorales and its use has been associated with breakthrough mucormycosis; fluconazole likewise lacks activity. Antibacterial therapy alone does not address the fungal angioinvasion.

    Reference: ECMM/MSG Global Guideline for the Diagnosis and Management of Mucormycosis (Cornely et al., Lancet Infect Dis, 2019)

  9. Question 9 · Cutaneous Neoplasms and Skin Cancer

    Four patients each have a single, clinically node-negative cutaneous squamous cell carcinoma. Which feature confers the highest risk of local recurrence and nodal metastasis and therefore warrants the most aggressive management and staging?

    1. AA 1.0 cm well-differentiated tumour on the forearm with 2 mm depth of invasion
    2. BA 1.4 cm well-differentiated tumour on the back with no perineural involvement
    3. CHistological perineural invasion of a named nerve measuring 0.15 mm in calibre
    4. DA 0.8 cm moderately differentiated tumour of the cheek confined to the papillary dermis
    Show answer and explanation

    Correct answer: C. Histological perineural invasion of a named nerve measuring 0.15 mm in calibre

    Large-calibre perineural invasion (nerves 0.1 mm or greater in diameter) is a major high-risk staging factor in both the Brigham and Women's Hospital and AJCC 8th edition systems and is strongly associated with local recurrence, nodal spread and disease-specific death, mandating wide or Mohs excision, nodal imaging and consideration of adjuvant radiotherapy. Small, well or moderately differentiated tumours with limited depth on the trunk, limbs or cheek without other adverse features are low-risk and are adequately treated by standard excision.

    Reference: AJCC Cancer Staging Manual, 8th ed. (2017); Karia PS et al., BWH tumour staging (JCO, 2014); NCCN Squamous Cell Skin Cancer (2024)

  10. Question 10 · Connective Tissue Disease, Dermal, Subcutaneous, Metabolic and Systemic Skin Disease

    In the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus, which requirement must be satisfied before the weighted additive criteria are counted?

    1. AA positive anti-double-stranded DNA antibody
    2. BAn antinuclear antibody titre of at least 1:80 on HEp-2 cells or an equivalent positive test
    3. CBiopsy-proven lupus nephritis
    4. DLow serum C3 and C4
    Show answer and explanation

    Correct answer: B. An antinuclear antibody titre of at least 1:80 on HEp-2 cells or an equivalent positive test

    The 2019 EULAR/ACR criteria use a positive ANA at a titre of at least 1:80 on HEp-2 cells (or an equivalent positive assay) as the obligatory entry criterion; only then are the weighted clinical and immunological domain items summed, with a score of 10 or more and at least one clinical criterion classifying the patient. Anti-dsDNA, low complement and biopsy-proven nephritis are individual weighted items, not entry requirements, and lupus nephritis class III/IV alone scores 10 but still needs the ANA entry criterion.

    Reference: Aringer M et al., 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus, Arthritis & Rheumatology / Annals of the Rheumatic Diseases (2019)

  11. Question 11 · Procedural, Surgical, Laser and Cosmetic Dermatology

    Shortly after a large-volume field infiltration of local anaesthetic, a patient complains of perioral numbness, metallic taste and tinnitus, then becomes agitated and has a generalised tonic-clonic seizure. Injection is stopped, the airway is supported with 100% oxygen and a benzodiazepine is given. Which additional intervention is most specific for this condition?

    1. AIntravenous 20% lipid emulsion bolus followed by an infusion
    2. BIntravenous flumazenil
    3. CIntravenous methylene blue 1 mg/kg
    4. DIntramuscular adrenaline 0.5 mg
    Show answer and explanation

    Correct answer: A. Intravenous 20% lipid emulsion bolus followed by an infusion

    This is local anaesthetic systemic toxicity, and after airway and seizure control the specific antidote is intravenous 20% lipid emulsion, which creates a lipid sink and supports myocardial function. Flumazenil reverses benzodiazepines and would worsen seizure control, methylene blue treats methaemoglobinaemia (a risk with prilocaine/benzocaine, not this presentation), and intramuscular adrenaline treats anaphylaxis, which would present with urticaria, bronchospasm and hypotension rather than prodromal neurological excitation.

    Reference: American Society of Regional Anesthesia and Pain Medicine (ASRA) Practice Advisory on Local Anesthetic Systemic Toxicity, 2018 update

  12. Question 12 · Hair, Nail, Adnexal and Mucous Membrane Disorders

    Culture from a patient with confirmed toenail onychomycosis grows Trichophyton rubrum. He takes no regular medications and has normal baseline liver enzymes. Which regimen is the most appropriate first-line systemic therapy?

    1. ATerbinafine 250 mg daily for 12 to 16 weeks with liver function monitoring
    2. BGriseofulvin 500 mg daily for 4 weeks
    3. CTopical amorolfine lacquer weekly alone for 12 weeks
    4. DOral ketoconazole 200 mg daily for 6 months
    Show answer and explanation

    Correct answer: A. Terbinafine 250 mg daily for 12 to 16 weeks with liver function monitoring

    Continuous terbinafine is the most effective and guideline-preferred systemic therapy for dermatophyte toenail onychomycosis, given for about 12 to 16 weeks with baseline and interval liver monitoring, since it is fungicidal against Trichophyton and persists in the nail plate after dosing stops. Griseofulvin requires 12 to 18 months for toenails with far lower cure rates. Topical lacquer monotherapy is reserved for superficial or limited distal disease without matrix involvement. Systemic ketoconazole is no longer used for dermatophyte infection because of hepatotoxicity and adrenal suppression.

    Reference: British Association of Dermatologists guidelines for the management of onychomycosis (2014); EMA restriction on oral ketoconazole (2013)

Dermatology reference books and guidelines

Every question in this bank names the textbook or guideline its answer rests on. These are the sources our Dermatology questions cite most often - the reading list to revise from alongside the bank.

Textbooks

10
  1. 1

    Bolognia, Jorizzo & Schaffer, Dermatology

    5th edition2024
  2. 2

    AJCC Cancer Staging Manual

    8th edition2017
  3. 3

    Fitzpatrick's Dermatology in General Medicine

    9th edition2019
  4. 4

    Rook's Textbook of Dermatology

    9th edition2016
  5. 5

    Paller & Mancini, Hurwitz Clinical Pediatric Dermatology

    6th edition2022
  6. 6

    Wolverton, Comprehensive Dermatologic Drug Therapy

    4th edition2021
  7. 7

    UAE and GCC health authority health-advertising licensing rules on prescription-medicine promotion

  8. 8

    Weedon's Skin Pathology

    4th edition
  9. 9

    Centre for Evidence-Based Medicine, NNT calculation

  10. 10

    Cochrane review of systemic antifungals for tinea capitis

    2016

Guidelines and standards

10
  1. 1

    CDC Sexually Transmitted Infections Treatment Guidelines, (Syphilis During Pregnancy)

    2021
  2. 2

    AAD-NPF guidelines of care for the management of psoriasis with biologics, J Am Acad Dermatol

    2019
  3. 3

    British Association of Dermatologists Guidelines for the Management of Tinea Capitis

    2014
  4. 4

    NCCN Guidelines for Cutaneous Melanoma

    2024
  5. 5

    AAD Guidelines of Care for the Management of Acne Vulgaris

    2024
  6. 6

    Ogawa, International Clinical Recommendations on Scar Management (updated consensus)

    2022
  7. 7

    General Medical Council, Guidance for Doctors who Offer Cosmetic Interventions

    2016
  8. 8

    Diagnosis and management of pemphigus: recommendations of an international panel of experts. J Am Acad Dermatol

    2020
  9. 9

    World Allergy Organization Anaphylaxis Guidance

    2020
  10. 10

    EAACI Guidelines: Anaphylaxis, Allergy

    2021

Where your regulator publishes a reading list, use the editions it names. Exam questions are not taken from any one book.

Last reviewed September 2026

About these questions: every question is original, researched by Neelim's exam research team, written to the published blueprint, with a rationale and a reference. No recalled or leaked exam content is used. How we write our questions.

Frequently asked questions

Are these real Dermatology exam questions?
No. Every item is original, researched by Neelim's exam research team against the exam blueprint published by the health authorities. Real, recalled or leaked exam content breaches the testing bodies' rules and can lead to a permanent exam ban - we do not sell it, and neither should anyone else.
How many questions are in the Dermatology bank?
Every bank starts at 3 full-length papers of roughly 155 questions each (the DHA exam itself is 150 questions), and you can add papers up to 6, including a bonus paper of our hardest questions. The papers do not overlap, so every question is new, and together they cover every sub-topic in the published blueprint.
What is the pass mark for the DHA Dermatology exam?
65%. DHA publishes the pass score for each exam, and 65% is the figure for Specialist Dermatology (DER5421) in the DHA CBT Guideline, Sep 2026. The result is posted to your Sheryan account as Pass or Fail only - your score is not shared. Elsewhere in the GCC: DOH Pass / fail only, SCFHS 65%, QCHP 65%, OMSB 65%, Kuwait MOH 65%.
How many questions are in the DHA Dermatology exam, and how long is it?
150 multiple-choice questions in 3 hours, and the time includes registration and the introduction. It is a computer-based test delivered by Prometric at test centres in the UAE and abroad.
How much does the DHA Dermatology exam cost?
USD 280 (about AED 1,030) per attempt, paid again for every re-sit. DHA also charges a flat AED 200 credentialing fee through Sheryan.
How many attempts do I get?
In the UAE, three in total across DHA, DOH, MOHAP and SHA, not three each, under clause 1.5.4 of the Unified PQR (April 2025). Clause 1.5.5 allows one further attempt with a different authority, except on the Consultant route. Elsewhere in the GCC: SCFHS up to 4 a year, QCHP 5 per scope, OMSB no set maximum, Kuwait MOH 3, 6 weeks apart.
Does this cover DHA, DOH, MOHAP, SCFHS and the other GCC regulators?
Yes, and it is not a generic set. Tell us which regulator you are sitting and we send the bank prepared for that authority's exam: its blueprint, its exam length and pass mark, and its local regulations. The core clinical knowledge is shared across the GCC; what changes by regulator is the test vendor (Prometric for DHA, SCFHS, QCHP, NHRA, Kuwait MOH; Pearson VUE for DOH, OMSB), the exam length, the pass mark, the local-regulation questions and, at some regulators such as DOH, an added oral or OSCE component. The table on this page shows each regulator's published format, pass mark and fee, and says where a figure is not published.
How do I receive it?
As PDF files. Card checkout is being set up, so for now you request it from this page and we send it to you directly, usually the same day.

Still unsure whether you even need this exam?

Your route depends on your profession, your licence title and the authority. We have guided over 1,000 professionals through GCC licensing - tell us your situation and we will confirm exactly what you need to sit.